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Ptchd1 deﬁciency induces excitatory synaptic and cognitive
dysfunctions in mouse
DC Ung1,2,21, G Iacono3,21, H Méziane4,21, E Blanchard1,5,6, M-A Papon1,2, M Selten7, J-R van Rhijn7, R Montjean8,9,10,11, J Rucci8,9,10,11,
S Martin12, A Fleet13, M-C Birling4, S Marouillat1,2, R Roepman14,15, M Selloum4, A Lux4, R-A Thépault1,2, P Hamel13, K Mittal16,
JB Vincent16, O Dorseuil8,9,10,11, HG Stunnenberg3, P Billuart8,9,10,11, N Nadif Kasri7,14, Y Hérault4,17,18,19,20,22 and F Laumonnier1,2,6,22
Synapse development and neuronal activity represent fundamental processes for the establishment of cognitive function.
Structural organization as well as signalling pathways from receptor stimulation to gene expression regulation are mediated by
synaptic activity and misregulated in neurodevelopmental disorders such as autism spectrum disorder (ASD) and intellectual
disability (ID). Deleterious mutations in the PTCHD1 (Patched domain containing 1) gene have been described in male patients with
X-linked ID and/or ASD. The structure of PTCHD1 protein is similar to the Patched (PTCH1) receptor; however, the cellular
mechanisms and pathways associated with PTCHD1 in the developing brain are poorly determined. Here we show that PTCHD1
displays a C-terminal PDZ-binding motif that binds to the postsynaptic proteins PSD95 and SAP102. We also report that PTCHD1 is
unable to rescue the canonical sonic hedgehog (SHH) pathway in cells depleted of PTCH1, suggesting that both proteins are
involved in distinct cellular signalling pathways. We ﬁnd that Ptchd1 deﬁciency in male mice (Ptchd1− /y) induces global changes in
synaptic gene expression, affects the expression of the immediate-early expression genes Egr1 and Npas4 and ﬁnally impairs
excitatory synaptic structure and neuronal excitatory activity in the hippocampus, leading to cognitive dysfunction, motor
disabilities and hyperactivity. Thus our results support that PTCHD1 deﬁciency induces a neurodevelopmental disorder causing
excitatory synaptic dysfunction.
Molecular Psychiatry (2018) 23, 1356–1367; doi:10.1038/mp.2017.39; published online 18 April 2017
INTRODUCTION
Intellectual disability (ID) and autism spectrum disorder (ASD) are
frequently associated neurodevelopmental disorders, which affect
at least 1% of the general population, and consequently represent
a major public health issue. From the past decades and the recent
development of next-generation sequencing, it has been well
established that4500 genetic factors are associated with ID and/
or ASD.1–5 Systems biology approaches have pointed toward the
involvement of synapse structure and function, chromatin
remodelling and regulation of protein synthesis in ASD and
ID.4–8 However, identifying the underlying pathophysiological
mechanisms remains a considerable challenge for many genes
mutated in these neurodevelopmental disorders.
Loss-of-function mutations (deletions, truncating mutations) in
the PTCHD1 (Patched domain containing 1) gene, located in the X
chromosome (Xp22.11), are found in male individuals presenting
with non-syndromic X-linked ID and/or ASD.9–12 A recent
phenotype–genotype correlation study on 23 patients with
PTCHD1 mutations established that they displayed mild-to-
moderate global developmental delay, variable degrees of ID
and 440% of them also show ASD or ASD-like behaviours.10
Recent estimates suggested that hemizygous PTCHD1 loss of
function might account for around 1% of patients with
neurodevelopmental disorders.13
In mammals, PTCHD1 belongs to a gene family including
PTCHD2 (also known as DISP3),14 testis-speciﬁc PTCHD315 and
PTCHD4 (also known as PTCH53).16 Little is known regarding the
speciﬁc function of the respective encoded proteins; however,
they display secondary structures similar to the Patched (PTCH1)
receptor, including 12 predicted transmembrane domains and a
sterol-sensing domain.9 In vitro studies have therefore suggested a
possible role of the PTCHD proteins in the regulation of sonic
hedgehog (SHH) signalling pathway, as well as their likely
localization at cell plasma membrane.9,16 SHH is a pleiotropic
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factor acting in the developing brain, including on axonal growth
and elongation.17 It has also been retrieved in synaptic terminals
and was shown to be involved in the regulation of dendritic spine
formation via a non-canonical pathway that directly regulates the
actin cytoskeleton.18,19 Finally, astrocyte diversiﬁcation in the adult
brain has been recently shown to directly depend on a neuronal
SHH signalling,20 suggesting a major contribution of this pathway
in developed and mature brains besides early neurodevelop-
mental processes.
The physiological role of PTCHD1 in the brain is poorly
described to date. Gene expression data from the Human
developmental transcriptome Brainspan project (www.brainspan.
org) indicate low expression levels of PTCHD1 in the developing
brain with the highest expression in postnatal cerebellum,
similarly to PTCH1 gene. Whole-genome transcriptional analyses
in the postnatal developing primate brain have recently shown
that PTCHD1 is highly expressed in neonatal cortex and striatum
(regions enriched in excitatory neurons) and decreases during
childhood.21 In mouse, a very recent study has indicated that
Ptchd1 was enriched, during the ﬁrst 2 weeks of life, in the
thalamic reticular nucleus, which is a structure containing
Parvalbumin-positive GABAergic neurons, and thereafter was
expressed more widely (cortex, cerebellum, hippocampus).13 Its
deletion was also shown to affect thalamic reticular nucleus
activity leading to attention deﬁcit and hyperactivity.13
Here we report that PTCHD1 is synaptically localized and
interacts with the postsynaptic membrane-associated proteins
PSD95 and SAP102 through a functional PDZ-domain-binding
motif, providing a direct link with the excitatory synaptic network.
The analysis of our Ptchd1− /y mouse model reveals structural and
functional alterations of excitatory synapses in the hippocampus,
as well as deregulation of the expression levels of numerous
synaptic genes and immediate-early expression genes. Besides the
previously described thalamic dysfunction associated with Ptchd1
knockout, we discovered that Ptchd1 deletion impairs hippocampal
activity. Our results thus support that PTCHD1 deﬁciency induces a
neurodevelopmental disorder, with disease pathogenesis resulting
from a deregulation of a neuronal pathway directly associated with
postsynaptic signalling complexes, and from disruption of the
excitatory synaptic organization in the developing brain.
MATERIALS AND METHODS
Molecular approach of Ptchd1 function
The expression proﬁle of Ptchd1 was assessed using the TissueScan
quantitative PCR-ready cDNA Arrays (Origene, Rockville, MD, USA;
Supplementary Methods). The Ptchd1 full-length sequence from IMAGE
cDNA clone 40095445 (Source BioSience, Nottingham, UK) was used for
green ﬂuorescent protein (GFP) fusion, deletion constructs and pulldown
strategy using the Pierce GST Protein Interaction Pull-down Kit (Fisher
scientiﬁc, Illkirch, France) to detect, respectively, PTCHD1 subcellular
localization and protein interactions (Supplementary Methods). Gli
transactivation activity was followed by Luciferase assay as described in
Supplementary Information.
Mouse line, ethical statement and in vivo functional studies
The Ptchd1− /y null allele was generated on the C57BL/6N genetic
background (Supplementary Figure S1 and Methods).22 The local ethics
committee, Com’Eth (no. 17), approved all mouse experimental proce-
dures, under the accreditation number 2012-139 and 2014-024. Functional
studies were performed between 3 and 4 months of age with two cohorts
of mutant mice and controls. Cohort 1 (11 Ptchd1− /y and 12 wild-type (WT)
littermates) was used to study the behaviour of animals, and cohort 2 (8
Ptchd1− /y and 8 WT males and 8 Ptchd1−/− and 8 WT females) was used for
more comprehensive analysis. Behaviour tests were run in the following
order between the age of 13 and 17 weeks: circadian activity, elevated plus
maze, novel object recognition, modiﬁed SmithKline Beecham, Harwell,
Imperial College, Royal London Hospital, Phenotype Assessment, grip test,
Rotarod test, Social recognition test, Y-maze spontaneous alternation,
auditory startle reﬂex reactivity and prepulse inhibition, Pavlovian fear
conditioning, hot plate test and shock threshold test, which are described
in Supplementary Information. Cohort 2 went through the IMPC pipeline
for broad-based analysis (http://www.mousephenotype.org/impress).23
Molecular characterization was carried by hippocampal expression
analysis by RNA sequencing in mutant and control littermates (P30) and
analysed as detailed in Supplementary Information.
Primary neuronal cultures
All mouse experiments were performed according to protocols approved
by the University Francois-Rabelais of Tours and INSERM. Brain tissues were
dissected from embryonic day 17.5 C57BL/6N WT or Ptchd1− /y mouse
embryos. The primary neuronal cultures were prepared as previously
described.24 Protocols for the morphological analysis of WT and Ptchd1
mutant neuronal cultures was performed as previously described.25
Brain ultra-structural analyses
Mice (a total of 3 WT and 3 Ptchd1− /y males, age 13–15 weeks) were
anaesthetized and were perfused transcardially with saline followed by
ﬁxative solution containing 4% paraformaldehyde and 2.5% glutaralde-
hyde in 0.1 M phosphate buffer (phosphate-buffered saline, pH 7.4). Brains
were dissected to obtain hippocampus, cortex and cerebellum and then
postﬁxed with a ﬁxative solution containing 4% paraformaldehyde and 1%
glutaraldehyde in 0.1 M phosphate buffer (pH 7.2) for 48 h. Tissues
were washed in phosphate-buffered saline, postﬁxed by incubation for
1 h with 2% osmium tetroxide and dehydrated in a graded series of
ethanol solutions. Samples were embedded in Epon resin, which was
allowed to polymerize for 48 h at 60 °C. Ultrathin sections were cut, stained
with 2.5% uranyl acetate and 1% lead citrate and deposited on electron
microscope grids for examination under a JEOL 1011 (Tokyo, Japan)
transmission electron microscope. Excitatory asymmetric synapses were
selected according to their typical structural organization, including the
presynaptic terminal characterized by the presence of numerous synaptic
vesicles, the synaptic cleft and a fuzzy electron-dense thickening of the
postsynaptic membrane deﬁning the postsynaptic density (PSD). Statistical
analysis was performed using the GraphPad Prism 6.0 software (La Jolla,
CA, USA).
Electrophysiological recordings of mEPSCs
Mice (3 WT and 3 Ptchd1− /y males, age P22–P23) were anaesthetized with
isoﬂurane before decapitation. Coronal slices (350 μm) were cut using a
HM650V vibration microtome (Fisher Scientiﬁc) in ice-cold artiﬁcial
cerebrospinal ﬂuid (ACSF) containing (in mM): 87 NaCl; 11 Glucose; 75
Sucrose; 2.5 KCl; 1.25 NaH2PO4; 0.5 CaCl2; 7 MgCl2; 26 NaHCO3,
continuously oxygenated with 95% O2/5% CO2 and incubated for 1 h at
32 °C. Slices were transferred to the recording setup 15 min prior to
recording and incubated at 32 °C while being continuously oxygenated
with 95% O2/5% CO2 in recording ACSF containing (unless otherwise
stated in mM): 124 NaCl, 1.25 NaH2PO4, 3 KCl, 26 NaHCO3, 10 Glucose, 2
CaCl2, and 1 MgCl2. Patch pipettes (3–5 MΩ) were made from borosilicate
glass capillaries and ﬁlled with intracellular solution containing (in mM): 115
CsMeSO3; 20 CsCl; 10 HEPES; 2.5 MgCl2; 4 Na2ATP; 0.4 NaGTP; 10 Na-
Phosphocreatine; and 0.6 EGTA. Traces were recorded using a Multiclamp
700B ampliﬁer (Molecular Devices, Sunnyvale, CA, USA), sampled at 10 kHz
and ﬁltered at 2 kHz. Cells were excluded from analysis if the series
resistance exceeded 25 MΩ. Miniature excitatory postsynaptic currents
(mEPSCs) were recorded at − 70 mV in the prescence of Tetrodotoxin
(1 μM) and Picrotoxin (100 μM). Paired pulse ratios (PPR) were recorded in
the presence of Picrotoxin (100 μM) in ACSF containing 4 mM CaCl2 and
4 mM MgCl2, at a holding potential of − 70 mV, following stimulation of the
Schaffer collaterals and calculated as peak2/peak1 after correcting for any
residual current at the second pulse. Miniature recordings were analysed
using the Mini Analysis Program (Synaptosoft, Fort Lee, NJ, USA). PPRs
were analysed using Clampﬁt 10.2 (Molecular Devices, Sunnyvale, CA, USA).
All drugs were purchased from Tocris (Minneapolis, MN, USA).
RESULTS
Ptchd1 gene expression converges with brain development and
synaptogenesis stages
Using real-time PCR, we found variable Ptchd1 expression in brain
areas, increasing from embryonic E13 stage to reach the highest
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levels at E18–P7 in most brain regions and decreasing in adult
stages except in cerebellar and hypothalamic regions similarly to
what is reported in primates21 (Figure 1). Surprisingly, we did not
detect any speciﬁc thalamic expression of Ptchd1 in our P7
samples, which might be explained by the use of two different
technical approaches for gene expression quantiﬁcation (quanti-
tative reverse transcriptase–PCR versus RNA in situ hybridization13)
as well as sample preparation (regional total mRNA extracts versus
brain slices13). Our results underscore a dynamic expression proﬁle
of Ptchd1 in the developing mouse brain, converging with
dendritogenesis and early synaptogenesis stages.
PTCHD1 is localized in dendritic spines and can interact with
postsynaptic scaffolds PSD95 and SAP102
Previous subcellular localization analyses reported that PTCHD1-
GFP (with GFP placed at the C-terminus of PTCHD1) expression in
cell lines is mostly detected at the plasma membrane.9 Yet such
analyses in neuronal cells are poorly described. We therefore
transiently expressed PTCHD1 constructs in primary hippocampal
neuronal cultures (11–14 days in vitro) with the GFP being placed
either at the N-terminus (GFP-PTCHD1) or at the C terminus
(PTCHD1-GFP). We showed that PTCHD1-GFP ﬂuorescence was
distributed throughout dendrites as a membrane-associated
Figure 1. Ptchd1 gene expression proﬁle in the mouse developing brain. Ptchd1 mRNA expression level was assessed by quantitative reverse
transcriptase–PCR on cDNA arrays (Origene) from 48 mouse cDNA extracted from telencephalon, frontal cortex, posterior cortex, entorhinal
cortex, olfactory bulb, hippocampus, striatum, mesencephalon, midbrain, rhombencephalon, pons, medulla, cerebellum, diencephalon,
thalamus, hypothalamus and spinal cord. Five developmental stages were investigated: E13, E15, E18, postnatal day 7 (P7), and adult week 5
(P35). Expression of Ptchd1 mRNA is shown relative to the Gapdh reference gene. Data are presented as mean± s.e.m., with median. Black or
red dot plots represent embryonic or postnatal stages, respectively. n= 3 independent experiments.
Figure 2. PTCHD1 (Patched domain containing 1) is a synaptic receptor interacting with PSD95 and SAP102 but does not modulate the
canonical sonic hedgehog signalling pathway. (a) Subcellular neuronal localization of PTCHD1-GFP (green ﬂuorescent protein) in primary
cultured hippocampal neurons. Representative images from confocal microscopy showing mature primary neurons expressing PTCHD1-GFP
protein displaying punctate ﬂuorescence throughout dendrites and dendritic spines. Hippocampal neurons were transfected at 12 days
in vitro with PTCHD1-GFP (wild type (WT)), PTCHD1-GFP lacking the last 39 amino acids (PTCHD1delCter-GFP) or the last 15 amino acids
(PTCHD1del874_888-GFP) and visualized 48 h later. Co-transfection with pDsRed was performed with PTCHD1delCter-GFP to visualize the
entire cell. PTCHD1-GFP, n= 15 neurons from 4 transfections; PTCHD1delCter-GFP, n= 11 neurons from 3 transfections; PTCHD1del874_888-
GFP, n= 6 neurons from 2 transfections. Scale bars: 50 μm and 10 μm for PTCHD1-GFP and PTCHD1del874_888-GFP, 20 μm for PTCHD1delCter-
GFP. (b) PTCHD1-GFP co-localizes with PSD95 in dendritic spines. Co-localization assay was performed using three primary neuronal cultures
transfected with PTCHD1wtGFP (green) at 11 days in vitro (DIV11) and ﬁxed at DIV14 and then immunostained with a mouse monoclonal
PSD-95 antibody and a secondary Donkey anti-Mouse antibody (Alexa Fluor 594, red). Co-localization signal in spines (yellow) is indicated by
white arrowheads. Data were collected from 10 transfected neurons with 31 dendrite sections in total (n= 3 independent transfections). Scale
bar: 10 μm. (c) Identiﬁcation of a PDZ-binding motif in the C-terminal tail of PTCHD1 allowing interaction with PSD95 and SAP102 proteins.
Predicted structure of PTCHD1 and sequence alignment of the 10 C-terminal amino acids of human proteins PTCHD1, PTCHD2, PTCHD3,
PTCHD4, PTCH1 and PTCH2. The PDZ-binding motif is shown in red. PTCHD1 and PTCHD4 C-terminal sequences are identical between human
and mouse. GST-pulldown assays using the C-teminal tail (39 amino acids) with or without the predicted PDZ-binding site as bait, and the
synaptoneurosomal lysates from adult WT mouse cortex lysates as the prey, evidenced for the presence of a speciﬁc interaction between the
predicted PDZ-binding motif and PSD95 and SAP102. The presence of a faint band in eluates from GST and from GST-Cter-delITTV using
SAP102 antibody was considered as the non-speciﬁc background. A total of three independent experiments were performed. (d) PTCHD1
does not repress Gli reporter activity in Ptch1−/− mouse embryonic ﬁbroblasts (MEFs). Luciferase activity was assessed in Ptch1−/− MEFs
co-transfected with PTCHD1-GFP or PTCH1, and an 8 × Gli Luciferase Reporter Plasmid. A constitutively active renilla luciferase plasmid was
also co-transfected to normalize for transfection efﬁciency. Luciferase values were measured using the Dual Luciferase Reporter Assay System
(Promega) and normalized to an empty GFP control vector. Data were evaluated using a one-way analysis of variance test followed by a
pairwise comparison of means using a Student’s t-test (with Bonferroni correction for multiple comparisons). Data are displayed as a box and
whisker plot with a central line for the median, a box comprised of the ﬁrst–third quartiles and whiskers showing the minimum and maximum
values. n= 3 independent experiments, with the displayed value for each being the average of duplicate plates of cells. *Po0.05.
PTCHD1 deﬁciency causes excitatory synapse dysfunction
DC Ung et al
1358
Molecular Psychiatry (2018), 1356 – 1367
labelling with a clear synaptic localization that was conﬁrmed by
PSD95 co-labelling experiments (Figures 2a and b). By contrast, we
found that the GFP-PTCHD1 ﬂuorescence was distributed uni-
formly, including in the nucleus (data not shown), suggesting that
GFP positioning would interfere with the membrane localization
of PTCHD1. We also tested a PTCHD1 construct with the GFP
inserted within the second extracellular loop but we were unable
to obtain any ﬂuorescence labelling, either in neurons or in
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HEK293 cell lines, possibly caused by conformational constraints
of the extracellular loop onto GFP structure (data not shown).
We then identiﬁed a potential PDZ-domain-binding motif
(‘ITTV’) localized at the C-terminal end of PTCHD1 (Figure 2c).
PDZ domain interactions normally require a free C-terminal end
and function in the dynamic trafﬁcking of synaptic proteins.26,27
Consequently, fusing the GFP to the C-term of PTCHD1 would hide
the PDZ interaction motif. The aberrant subcellular ﬂuorescent
signals of the other constructs, despite displaying a free PDZ
motif, prompted us to use PTCHD1-GFP as the only experimental
approach to further investigate its subcellular localization.
Interestingly, we observed that PTCHD1-GFP lacking its
C-terminal intracellular tail (PTCHD1delCter-GFP) failed to target
to synapses, indicating that the corresponding last 39 amino acids
would be required for dendritic and synaptic targeting (Figure 2a).
Furthermore, the deletion of the C-terminal 15 amino acids did
not affect dendrite and synapse trafﬁcking of PTCHD1-GFP
(Figure 2a), which suggests that an essential targeting element
resides within a 24 amino-acid cytoplasmic segment (amino-acid
residues 850–873) that is enriched in charged amino acids
(6 Lysine and 6 glutamic acid).
The predicted PDZ interaction site identiﬁed in PTCHD1 is also
present in synaptic EXOC4 protein where it binds the postsynaptic
scaffolds PSD95 and SAP102 proteins,28 which are essential for
excitatory synapse formation and function.26,27 To assess whether
PTCHD1 C-terminus bears similar interaction properties, we carried
out GST-pulldown interaction studies using the C-terminal tail of
PTCHD1 as bait. As shown in Figure 2c, PSD95 and SAP102 proteins
speciﬁcally interact with PTCHD1, and these interactions require the
C-terminal PDZ-binding motif as its deletion abolished their bindings.
Notably, this motif is absent in all other Patched domain-related
proteins (including PTCH1) except for PTCHD4 (Figure 2c), reﬂecting
a possible evolutionary divergence in function.
Whereas PDZ domain interactions normally require a free
C-terminal end, our ﬁndings using the PTCHD1-GFP fusion protein
indicate that its synaptic targeting is not driven by the
PDZ-binding motif. These results thus suggest that postsynaptic
targeting of PTCHD1 is not speciﬁcally mediated by the
scaffolding action of PSD95 or SAP102. Similar ﬁndings were
previously described for the excitatory postsynaptic NLGN1-GFP
and NR1-GFP proteins, also known to interact with PSD95.29,30
Altogether these data indicate that PTCHD1 is partly localized at
synapses. The C-terminal intracellular tail is essential for the
dendritic sorting of PTCHD1, whereas its binding to the key
molecules of synapse assembly PSD95 and SAP102 would not be
strictly required for its synaptic targeting.
PTCHD1 does not activate canonical SHH pathway in Ptch1−/−
mouse embryonic ﬁbroblasts
A major question remains regarding the direct contribution of
PTCHD1 to the SHH signalling pathway. We performed
Gli-luciferase reporter assays that are standardly used to measure
canonical SHH signalling in mouse embryonic ﬁbroblasts isolated
from Ptch1− /− embryos. Intrinsic levels of SHH signalling in these
cells are extremely high, due to the absence of PTCH1, which
normally acts to keep the pathway in a repressed state.31 As
Figure 2d shows, reconstitution of PTCH1-deﬁcient mouse
embryonic ﬁbroblasts with PTCH1 greatly represses canonical
pathway activity as measured by Luciferase transcription from the
Gli1 promoter. In stark contrast, expression of PTCHD1 in these
same cells failed to repress the Gli1-Luciferase reporter construct,
indicating that PTCHD1 does not compensate for the absence
of PTCH1 and has no ability to repress canonical SHH signalling.
These ﬁndings therefore suggest that, despite its similarity
with the PTCH1 receptor, PTCHD1 is unable to regulate the
SHH-signalling pathway indicating that it would not be a SHH
receptor.
Disruption of Ptchd1 in mouse impairs cognitive function and
motor abilities and induces hyperactivity
To provide further insights into the neurodevelopmental role of
PTCHD1, we generated a mouse model invalidated for the Ptchd1
gene caused by the excision of the second exon (Supplementary
Methods; Supplementary Figure S1a). We conﬁrmed that the full-
length Ptchd1 transcript was absent in Ptchd1− /y mice using
quantitative reverse transcriptase–PCR and total RNA sequencing,
and we observed a remaining and weak expression of an
alternative transcript skipping exon 2 (Supplementary Figure S1b).
Ptchd1− /y males and Ptchd1− /− females were characterized on
several aspects of central nervous system functions. Mutant males
displayed a signiﬁcant increase in food consumption (Po0.05;
Supplementary Figure S2a), with a slight tendency of increased
body weight (P= 0.10), and decreased grip strength (P= 0.01)
compared with WT littermates (Supplementary Table S1).
Increased body weight and altered motor abilities were supported
in additional cohorts of Ptchd1− /y males (P40.05) (Supplementary
Table S2). Decreased muscle strength in Ptchd1− /y males is in line
with previously reported data,13 replicating hypotonia observed in
patients.10 In addition, Ptchd1− /y males displayed altered rotarod
performance supporting impaired motor coordination observed in
patients.10 Ptchd1− /y males showed a signiﬁcant increase in
locomotor activity (Figure 3a) and rears (not shown) throughout
the whole testing period in the circadian activity test (Po0.05).
Ptchd1− /y males also exhibited a signiﬁcant increase in local
Figure 3. Ptchd1− /y males are hyperactive, show reduced anxiety and exhibit altered cognitive abilities in different learning paradigms. (a)
Locomotor activity in the circadian activity over 35 h of testing presented per hour period and as a total during each phase of the cycle (n= 12
wild-type (WT) and 11 Ptchd1− /y mice; results are expressed as mean± s.e.m. for evolution graph or as a scattergram with the median;
*Po0.05, **Po0.01, ***Po0.001 from WT, unpaired Student’s t-test); (b) locomotor activity and rears in the open ﬁeld (n= 12 WT and 11
Ptchd1− /y mice; results are expressed as a scattergrams with the median; *Po0.05, **Po0.01, from WT, unpaired Student’s t-test); (c) the
number of visits in the social recognition test (n= 12 WT and 11 Ptchd1− /y mice; results are expressed as a scattergram with the median;
***Po0.001 from WT, unpaired Student’s t-test); (d, e) anxiety-related behaviour as measured by the percentage of time in the centre of the
open ﬁeld arena (d), and by the percentage of entries and time in the open arms in the elevated plus maze (e) (n= 12 WT and 11 Ptchd1− /y
mice; results are expressed as scattergrams with the median; *Po0.05, from WT, unpaired Student’s t-test); (f) working memory performance
(n= 12 WT and 11 Ptchd1− /y mice; results are expressed as a scattergram with the median; *Po0.05 from WT, unpaired Student’s t-test); (g)
duration of object exploration during acquisition (n= 12 WT and 11 Ptchd1− /y mice; results are expressed as a scattergram with the median;
unpaired Student’s t-test), and object recognition performance during retention (n= 12 WT and 11 Ptchd1− /y mice; results are expressed as a
scattergram with the median; §Po0.05 signiﬁcantly different from Hasard (50%), one group t-test); (h) duration of immobility during
habituation to the conditioning cage and during context in the fear conditioning and contextual and cued freezing performance (n= 8 WT
and 8 Ptchd1− /y mice; results are expressed as mean± s.e.m.; repeated analysis of variance (ANOVA) followed by unpaired Student’s t-test for
each time point; ANOVA for baseline habituation: gene F(1,14)= 8.01, P= 0.013, time F(1,14)= 2.61, P= 0.129, interaction F(1,14)= 0.852,
P= 0.372; ANOVA for contextual fear: gene F(1,14)= 10.01, P= 0.0069, time F(1,14)= 0.897, P= 0.419, interaction F(1,14)= 0.467, P= 0.632;
ANOVA for cued fear: gene F(1,14)= 3.67, P= 0.076, time F(1,14)= 7.994, P= 0.0134, interaction F(1,14)= 0.149, P= 0.705).
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activity in the rear part of the cages during the dark phase of the
circadian cycle (Po0.05) (Supplementary Figure S2c), which might
be interpreted as stereotypic behaviour. Increased activity in
Ptchd1− /y males was also observed in other situations, as revealed
by an increase in travelled distance and higher number of rears in
the open ﬁeld (Po0.05; Figure 3b) and higher number of
congener or object box entries in the social recognition test
(Po0.001; Figure 3c). Increased activity in Ptchd1− /y males in the
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open ﬁeld was replicated using a new sets of mice and
was also found in Ptchd1−/− females (Po0.001; Supplementary
Figure S2b).
Our ﬁndings conﬁrm those previously reported13 and, impor-
tantly, extend the robustness of hyperactivity phenotype in other
situations, including circadian measurement of activity, or in social
Figure 4. Analysis of the hippocampal transcriptome of Ptchd1− /y reveals global increased expression of synaptic genes. (a) Clear segregation
of wild-type (WT) and Ptchd1− /y transcriptomes. Clustering of Pearson correlations (Ward’s linkage), an unbiased method to quantify the
degree of similarity between data set, shows clear segregation between genotype and high concordance of biological replicas. (b)
Upregulated genes impact the neuronal populations in the hippocampus. Radar plot representing the enrichments (hypergeometric test,
Bonferroni corrected) of cell-type-speciﬁc markers35 (see Supplementary Methods) in the lists of upregulated and downregulated genes. Outer
rings correspond to higher enrichments (P-values represented in Z-score scale). Red and blue shape occupy largely separated areas, that is, cell
types. (c) Ptchd1 inactivation is associated with the upregulation of synaptic genes. Radar plot summarizing the major gene ontology (GO)
enrichments for upregulated and downregulated genes. Outer rings correspond to stronger enrichments. Bonferroni-corrected P-values are
represented in Z-score scale. Upregulated genes are strongly enriched in synaptic proteins while downregulated genes seem to be implicated,
among other pathways, in the mitochondrial respiratory chain and the SRP-dependent co-translational protein targeting to membrane. (d)
Detailed overview on the synaptic and neurodevelopmental genes upregulated in Ptchd1− /y hippocampi. Histogram showing the Bonferroni-
corrected P-values for the selected GO enrichments. The numbers indicate the amount of genes annotated with each term in the upregulated
gene set and genomewide, respectively. Almost 25% of the PSD genes are upregulated in Ptchd1− /y hippocampi. (e) Enrichments for
experimental binding sites from Cistrome chromatin immunoprecipitation-seq database. Upregulated genes are enriched in the binding sites
of Suz12, Acsl1 and Rest, whereas downregulated genes are not. Complete data in Supplementary Table S9.
Figure 5. Impairments of synaptic morphology and activity in Ptchd1− /y mice. (a) Altered morphology of primary embryonic hippocampal
cultures from Ptchd1− /y embryos. Quantiﬁcation of dendritic lengths, branching numbers and complexity from green ﬂuorescent protein
(GFP)-labelled hippocampal neurons at 18 days in vitro between wild-type (WT) and Ptchd1− /y littermate embryos. Scale bar: 10 μm. Data are
presented as mean± s.e.m., n= 21 WT and 20 Ptchd1− /y neurons. *Po0.05 and **Po0.01, Mann–Whitney (length of branches: P= 0.005; and
number of branches: P= 0.0452) and two-way analysis of variance with Sidak's multiple comparisons (branching complexity: level 1, P40.999;
level 2, P40.999; level 3, P= 0.9668; level 4, P= 0.4663; level 5, P= 0.0119; level 6, P= 0.0004) tests. (b) Reduced synaptic density in
hippocampus from Ptchd1− /y mice. Representative electron micrographs (EM) of synaptic contacts from hippocampal sections. Scale bar:
200 nm. Quantiﬁcation of postsynaptic densities (PSDs) performed on a deﬁned plane of 65 μm2. A total of 3 WT and 3 Ptchd1− /y brains
(31 sections for each genotype representing 8–13 sections per animal). Graphical data are presented as scatter plots representing sections
analysed for each animal± s.e.m., **Po0.01 (exact P= 0.0085, calculated using the mean values per animal); unpaired two-tailed Student’s
t-test. (c) Altered morphology of the excitatory synapses in Ptchd1− /y mice. Higher magniﬁcation of EM is shown (white bars, dotted bars and
white arrows indicate synaptic cleft width, PSD length and PSD width, respectively). All analysed excitatory synaptic junctions were deﬁned by
an asymmetric structural organization, including well-deﬁned presynaptic (for example, vesicles) and postsynaptic (PSD) structures. Scale bars:
200 nm and 50 nm. (d) Comparison of the cumulative frequency for PSD length and width and for synaptic cleft width in WT and in Ptchd1− /y
hippocampi. A total of 3 WT brains (86 synapses splitted in 19, 30 and 37 structures in the respective brains) and 3 Ptchd1− /y brains (79
synapses splitted in 17, 26 and 35 in the respective brains) were analysed. Graphical data are presented as mean cumulative frequency curves
obtained for each genotype± s.e.m.. Kolmogorov–Smirnov test; PSD length, P= 0.4154; PSD width, P= 0.0310; synaptic cleft width, P= 0.0008.
(e–i) Reduced miniature excitatory postsynaptic current (mEPSC) frequency and increased release probability in Ptchd1− /y mice. Example
traces (e) and quantiﬁcation of mEPSC amplitude (f) and frequency (g). Example traces (h) and quantiﬁcation (i) of paired pulse ratio. Sample
size (n) is indicated in the bars as cells per animals. Data are presented as mean± s.e.m., **Po0.01. Student’s t-test. KO, knockout.
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test conditions. In addition, we found that Ptchd1− /y males had an
increased number of rears in the actimetric cages and in the open
ﬁeld (Figure 3a and Supplementary Figure S2b), a parameter
reﬂecting stereotypic behaviour,32 in line with clinical observations
and common features of attention deﬁcit and hyperactivity
disorder (ADHD) or ASD syndrome.10
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When analysed for emotional behaviour in the elevated plus
maze, the percentage of entries and time (Po0.05) spent in the
open arms by Ptchd1− /y males were increased when compared
with WT (Figure 3e). Ptchd1− /y males also displayed higher
number of entries (Po0.01) (not shown) and spent more time in
the centre of the open ﬁeld than WT (Po0.05) (Figure 3d),
supporting reduced anxiety in mutants. Such effect was conﬁrmed
using another cohort on Ptchd1− /y males (Po0.001) but was not
observed in Ptchd1−/− females (Supplementary Figure S2b). To the
best of our knowledge, our study show for the ﬁrst time that
Ptchd1 deletion reduced anxiety in Ptchd1− /y male mice. Social
behaviour was not affected in (Supplementary Figure S3a), in line
with previously published data.13
No consequences of Ptchd1 deletion on acoustic startle and
prepulse inhibition of startle reﬂex were detected (Supplementary
Figure S3b), suggesting that the overall ability to ﬁlter out the
unnecessary information is preserved in the mutant mice.
The effects of Ptchd1 gene inactivation were also evaluated on
different aspects of learning and memory processes. When
animals were allowed to discriminate between a novel object
and a familiar one 3 h after an acquisition trial, only WT, but not
Ptchd1− /y mice, displayed object recognition performance above
the chance (Figure 3g), suggesting altered recognition memory
following Ptchd1 inactivation in males. Ptchd1− /y males also
showed altered working memory in the Y-maze test, as revealed
by signiﬁcantly reduced percentage of spontaneous alternations
(P40.05; Figure 3f). These data are in line with attentional and
cognitive features in developmental diseases, including ADHD and
ASD syndromes.33,34 In the fear conditioning test, the baseline
levels of immobility during habituation to the conditioning cages
was lower in Ptchd1 mutants as compared with WT (Po0.01),
supporting the hyperactivity observed in the other behavioural
tests (Figure 3h). When animals were tested 24 h after condition-
ing either in the same context or in a new one, Ptchd1− /y males
showed signiﬁcantly decreased contextual freezing performance
(Po0.01) and tended to have decreased cued freezing perfor-
mance (P= 0.07; Figure 3h). Ptchd1−/− females also showed
decreased contextual and cued fear conditioning (Po0.01;
Supplementary Figure S3c). All these data suggest that Ptchd1
inactivation in males (and also in females) impact learning and
memory processes as recently reported13 and greatly extend the
cognitive deﬁcits to Ptchd1−/− females and to other cognitive
domains such as learning and memory with object recognition
and associative memory.
Dysregulation of the hippocampal synaptic transcriptome in the
Ptchd1− /y mouse brain
The hippocampus is a hub involved in various learning and
memory processes that are affected in the mutant Ptchd1 mouse
line. Thus we characterized the impact of Ptchd1 deﬁciency on the
hippocampal transcriptome at postnatal day 30. We conﬁrmed
that Ptchd1 mRNA (NM_001093750) level was strongly decreased
in Ptchd1− /y brain (Z score: − 8.87, expression fold change
Ptchd1− /y vs Ptchd1+/y: − 2.43) with a remaining expression of
exon 3, revealing the presence of an alternative transcript skipping
exon 2 (Supplementary Figure S1). Strikingly, the comparative
analysis of RNA-seq data indicated that a very large number of
genes are aberrantly expressed in the Ptchd1− /y hippocampus
when compared with WT males. A total of 979 genes were
upregulated and 820 genes were downregulated in Ptchd1− /y
(Po0.01, DEseq2, mature transcripts; Supplementary Table S3).
Clustering of Pearson correlations clearly segregated genetic
conditions while associating biological replicates (Figure 4a).
We next performed a bioinformatics analysis based on
published single-cell data35 for determining which cell types
should be affected in Ptchd1− /y hippocampus. Statistical analysis
of markers of cell types (see Supplementary Methods) revealed
that upregulated genes are signiﬁcantly enriched in markers of
neuronal cells (pyramidal neurons 59 genes/Po1.8e-14, inter-
neurons 23 genes/Po9.3e-6) while downregulated genes are
signiﬁcantly enriched in markers of glial and endothelial cells
(astrocytes 28 genes/Po3.7e-5, oligodendrocytes 40 genes/
Po1.8e-7, endothelial 26 genes/Po7.7e-3) (Figure 4b; Supplem-
entary Tables S4–S8). This bioinformatic evidence links Ptchd1− /y
upregulated genes to neuronal populations. Also gene ontology
supports this link, as gene ontology enrichment analysis revealed
that upregulated genes are highly enriched in presynaptic and
postsynaptic proteins (Figure 4c). In particular, the most striking
observation was the aberrant upregulation of the expression of a
very large portion of PSD-associated genes (almost 25% of the
total, Figure 4d), such as Dlg4 (encoding PSD95) or Shank1, 2 and
3. A large portion of presynaptic genes was also upregulated (20%
of the total), including Syt1, Bsn and Vamp2. Upregulated genes
also appeared linked to brain development including axonogen-
esis and dendritogenesis (Figure 4d) and, when altered, should
perturb the synaptic function. Upregulated genes also include
highly signiﬁcant amounts of transcription factors and chromatin
remodelling factors (including the immediate-early genes Egr1
and Npas4 that have an increased expression level by about 50%
in Ptchd1− /y mice, Supplementary Table S3) and appeared to be
markedly implicated in the development of the central nervous
system (Figures 4c and d).
Analysis of in silico-binding sites (MotifMap36) and cistrome
(www.cistrome.org) experimental data (chromatin immunoprecipi-
tation-seq) for transcription factors reveals that largely dissociated
networks of transcription factors seem to regulate Ptchd1− /y
upregulated and downregulated genes (Supplementary Table S9).
For example, a release of the repression induced by Polycomb
group proteins such as REST (which suppresses the transcription of
many neuronal genes) and SUZ12 could be implicated in the
aberrant upregulation of several genes in Ptchd1− /y mice
(Figure 4e).
Impaired excitatory synaptic structure and activity in
Ptchd1− /yhippocampus
The comparative in vitro analysis of neuronal morphology for both
WT and Ptchd1− /y mature primary hippocampal cells (18 days
in vitro) revealed signiﬁcant differences in the dendritic length and
in the number of branches, with Ptchd1− /y neuronal cultures
displaying a decreased dendritic arborization compared with WT
cultures, suggesting that the absence of Ptchd1 might affect
neuritic/dendritic development (Figure 5a).
We then performed in situ ultra-structural analyses of hippo-
campal sections from young adult (13–15 week old) Ptchd1− /y
males using transmission electron microscopy (Figures 5b–d). We
ﬁrst observed a decrease in the number of excitatory synapses in
the Ptchd1− /y brain, leading to a diminution of around 33% of the
synapses (mean WT= 21.9 ± 0.835 s.e.m.; mean Ptchd1− /y:
15.6 ± 1.004 s.e.m. in an arbitrary deﬁned ﬁeld section of 65 μm2;
31 sections/3 mice for each genotype, unpaired Student’s t-test,
P= 0.0083; Figure 5b).
The loss of Ptchd1 also resulted in ultra-structural deﬁcits in
excitatory synapses when analysing the cumulative frequency
distribution, including a reduction of both PSD thickness
(WT, 54.72 ± 2.7 nm s.e.m.; Ptchd1− /y, 37.42 ± 1.23 nm s.e.m.,
Kolmogorov–Smirnov test, Po0.0001) and synaptic cleft width
(WT: 18.19 ± 0.37 nm s.e.m.; Ptchd1− /y, 15.50 ± 0.57 nm s.e.m.,
Kolmogorov–Smirnov test, Po0.01), when compared with WT
hippocampal synapses (Figure 5d). The most striking difference
between WT and Ptchd1− /y synapses was the strong accumulation
of neurotransmitter vesicles in Ptchd1− /y synaptic boutons
(Figure 5c). Our combined results therefore indicated that Ptchd1
deﬁciency signiﬁcantly affects the structural maturation and
organization of excitatory neuronal synapses.
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To examine the physiological consequences of these ultra-
structural changes, we recorded mEPSCs from CA1 pyramidal
neurons from P21 WT and Ptchd1− /y mice (Figures 5e–g). We
found no changes in mEPSC amplitude (Figures 5e and f), but a
signiﬁcant decrease in mEPSC frequency in Ptchd1− /y compared
with WT mice (Figures 5e and g). We next assessed the release
probability of Schaffer collateral axons, the main excitatory input
onto CA1 pyramidal cells, by PPR. We found that the PPR is
signiﬁcantly decreased in Ptchd1− /y compared with WT brain, thus
revealing an increased release probability at these synapses
(Figures 5h and i). Together, these data indicate that pyramidal
cells receive a reduced number of excitatory synapses in Ptchd1− /y
mice but that these synapses present a higher release probability.
DISCUSSION
Although pathogenic mutations in PTCHD1 gene have been
described in a signiﬁcant number of individuals and families with
ASD and X-linked ID to date, the physiological function and
contribution of the respective gene and protein during central
nervous system development are poorly documented.
Here we provide several lines of evidence indicating that
PTCHD1 is a novel synaptic player that is able to interact with
postsynaptic membrane-associated scaffolding proteins, such as
PSD95 and SAP102. Furthermore, PTCHD1 impacts on the
expression level of synaptic genes, as Ptchd1 deﬁciency in mouse
is associated with a global impact on the hippocampal memory
function associated with dysregulation of synaptic transcriptome.
Besides recent published ﬁndings that highlighted a major role of
PTCHD1 in the reticular thalamic nucleus in developing mouse
brain,13 we also observed that the neurodevelopmental PTCHD1
gene expression proﬁle and pattern partly differed between
primates (human and macaques) and mouse. Several studies
suggested that these differences would reﬂect many primate-
speciﬁc features of cortical development.21,37,38
Our subcellular localization study was performed using
PTCHD1-GFP with the GFP inserted at the C-terminal end of
PTCHD1. Although we observed that PTCHD1-GFP was enriched in
synaptic structures and displayed a plasma membrane labelling,
we must consider that the PDZ-binding motif might be not
functional, because of the position of the GFP, in transfected
neurons as PDZ domain interactions normally require a free
C-terminal end. To circumvent this limitation, we tested other
PTCHD1 constructs with GFP included at the N-terminus or
inserted in the second extracellular loop, but we were unsuccess-
ful to obtain any membrane/synaptic localization or any
ﬂuorescence in transfected cells. Finally, despite several attempts
of PTCHD1 antibody production (using a strategy of various
peptides combinations), we were also unable to obtain excellent
speciﬁc PTCHD1 antibody to assess endogenous PTCHD1 neuronal
localization by immunoﬂuorescence analysis. Consequently, our
conclusions regarding the subcellular localization of PTCHD1-GFP
have to be taken with this caveat in mind. Further work would
provide evidence to validate the endogenous interaction between
PTCHD1 and PSD95/SAP102 proteins through the PDZ-binding
motif that might contribute to PTCHD1 dynamics, trafﬁcking and
stability in synapses. The generation of highly speciﬁc antibodies
against PTCHD1 will help into the detailed characterization of its
neuronal subcellular localization.
We discovered that Ptchd1 gene expression appears essential to
the functional organization of excitatory synapses in the mouse
hippocampus. We observed that both Egr1 and Npas4 genes were
upregulated in the Ptchd1− /y hippocampus. Unlike Egr1, Npas4 is
expressed exclusively in neurons where it is able to modulate
GABAergic, glutamatergic or both types of synapses.39,40 Further-
more, it has been demonstrated that Npas4 overexpression in
hippocampal neuronal cultures increased the number of inhibitory
synapses, suggesting that higher Npas4 level result in more
inhibition and less excitation, leading to reduced excitability of
hippocampal neurons.39 These ﬁndings suggest that Ptchd1
deﬁciency not only cause defects targeting thalamic GABAergic
neurons13 but also induce alterations in synaptic homeostasis
(that is, excitatory/inhibitory (E/I) balance) through Npas4
increased expression level. Npas4 would be a major actor that
maintains the E/I balance of neural circuits by recruiting inhibitory
synapses onto excitatory neurons and excitatory synapses onto
inhibitory neurons in response to increased activity.41
We also found that PTCHD1 includes a functional PDZ-binding
site allowing direct interactions with core scaffolding proteins of
the excitatory PSD proteome, such as PSD95 and SAP102. Similar
receptor–scaffold associations also involve N-methyl-D-aspartate
(NMDA) receptors, Neuroligins 1, 3 and 4, which are the major
components for excitatory synapse formation and function.
Interestingly, PTCHD4 protein harbours a predicted consensus
PDZ-binding site (Figure 1b). This interaction domain is absent in
PTCH1 receptor, which suggests that PTCHD1 is probably involved
in a speciﬁc signalling pathway distinct from the canonical SHH
cascade, as initially hypothesized.42
Kim et al.42 observed that Ptchd1 mRNA expression level was
found strongly upregulated in mouse primary cortical neuronal
cultures exposed during 6 h to an elevated level of potassium
chloride (KCl, 55 mM) causing a membrane depolarization and
neuronal activation. Similar results were obtained for Grin1,
encoding the NMDA receptor subunit 1, and suggest that Ptchd1
expression could be modulated by neuronal activity.
Whether PTCHD1 is a receptor for SHH remains a question that
will require future work. Interestingly, SHH signalling is functional
in developing neurons where it regulates spinogenesis and axonal
growth.43,44 A very recent study evidenced that SHH can inhibit
glutamate transporter activities in neurons and is able to
modulate neuronal activity in hippocampal cultures and slices.45
However, our results suggest that PTCHD1 might not bind SHH
given its incapacity to rescue PTCH1 deﬁciency to activate the
canonical SHH pathway (that is, Gli-dependent) and because it
does not include the SHH ligand-binding site that is present in
PTCH1 (LTKQRLVDADG, amino acids 888–898 in human PTCH1,
NP_032983).46
Comprehensive clinical analysis of patients with PTCHD1
mutation described several symptoms ranging from attention
deﬁcit, hyperactivity, sleep abnormality, hypotonia and learning
disability.10 In line with clinical data, our ﬁndings show that Ptchd1
deﬁciency caused hyperactivity, decreased muscle strength,
altered motor coordination and cognitive dysfunction, conﬁrming
phenotypes previously described in Ptchd1-deﬁcient mice13 and
extending the list of common features in patients with PTCHD1
mutations.10
The behavioural ﬁndings in our mouse model are not a simple
replication of previously described phenotypes in Ptchd1− /y
males,13 but thorough characterization of alterations consecutive
to Ptchd1 deletion in mice. First, our ﬁndings extend the
robustness of hyperactivity phenotype not only in the open ﬁeld
(as described by Wells et al.13) but also in other situations,
including circadian measurement of activity, or in social test
conditions. Hyperactivity was also observed in Ptchd1−/− female
mice. In addition, we found that Ptchd1− /y mutants exhibited a
signiﬁcant increase in local activity in the rear part of the cages
during the dark phase of the circadian cycle, an interpreted
stereotypic behaviour. Mutants also had increased number of
rears in different situations, considered as a repetitive motor
behaviour and classically used to reﬂect stereotypic behaviour in
addition to other parameters.32 Increased stereotypic behaviour is
a common feature of ASD and ADHD, in line with clinical
observations.
Furthermore, we found hypotonic-like behaviour and motor
coordination deﬁcits (rotarod, startle response) extending pub-
lished data and replicating features described in patients with
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PTCHD1 deﬁciency.10,13 Circadian activity measurements also
revealed increased activity during the light phase suggesting
altered sleep, similarly to the clinical observations.10 When looking
at cognitive abilities, our data reveal speciﬁc alteration in working
memory, in line with attentional and cognitive features in
neurodevelopmental disorders, including ADHD and ASD. Indeed,
executive dysfunction (including working memory) is considered a
promising endophenotype in neurodevelopmental disorders, such
as ASD and ADHD (for a review, see Craig et al.47). However,
contrasting results were reported: working memory deﬁcits were
more pronounced either in ASD or in ADHD depending on the
studies; even deﬁcits were not observed in some studies reporting
ASD or ADHD clinical investigations.47 Our results are consistent
with potential deﬁcits described either in ASD or ADHD.
Finally, our study did not focus only on males but describes
interesting phenotypes both in males and females, while others
are speciﬁc to males such as reduced anxiety. Considering the
X-linked inheritance model of PTCHD1 mutations, most cases are
males. Among 23 cases described so far,10 only one is a female
who was described to have speech delay and a formal diagnosis
of ASD, while males had more extended features. Our data are in
line with these clinical observations, with Ptchd1−/− female mice
without obvious neurological abnormalities.
In summary, the analysis of our Ptchd1− /ymouse model revealed
structural and functional impairments at excitatory synapses as
well as behavioural and cognitive alterations. Our observations
indicated that Ptchd1 deﬁciency causes defects in the structural
organization of synapses during brain development. We replicated
cognitive deﬁcits (fear conditioning deﬁcits) previously reported13
and also found working memory deﬁcits, which is supposed
to be an attentional-dependent ability, altered in ADHD/ASD
conditions.33,34 Finally our data evidenced for the ﬁrst time that
Ptchd1 deletion in female mice also caused ADHD-like hyperactive
behaviour and learning and memory deﬁcits.
It will be of major interest to better understand in future studies
the speciﬁc contribution of PTCHD1 gene and protein at the
synapse, in spine formation and synaptic maintenance and/or
communication.
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